Genetic testing company Natera (NASDAQ: NTRA) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 37.7% year on year to $752.8 million. The company’s full-year revenue guidance of $2.88 billion at the midpoint came in 3% above analysts’ estimates. Its non-GAAP loss of $0.47 per share was 12% above analysts’ consensus estimates.

Is now the time to buy NTRA? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Natera’s second quarter results were positively received by the market, driven by robust sales volume growth and ongoing momentum in both established and emerging product lines. Management attributed the quarter’s strength to record-breaking test volumes—particularly for Signatera in oncology—and the successful launch of an enhanced Panorama prenatal test. CEO Steven Chapman highlighted increased adoption across tumor types and cited critical milestones, including FDA and Japanese regulatory approvals for Signatera, as key contributors to elevated clinical adoption. The quarter also saw a notable improvement in gross margins, which management linked to higher average selling prices and the scaling of recently launched products.

Looking forward, Natera’s guidance is shaped by anticipated volume growth across its core testing franchises and steady advances in reimbursement and clinical adoption. Management expects ongoing investments in clinical trials and R&D, particularly in early cancer detection, to drive future growth. CFO Michael Brophy noted, “The ambition is to have gradual improvement in ASPs as new coverage policies come online, especially with broader MolDX indication coverage and further guideline inclusions.” Additional catalysts include the commercial rollout of Signatera in Japan and the expected readouts from multiple prospective studies, which are viewed as key to unlocking new reimbursement opportunities and expanding addressable markets.

Key Insights from Management’s Remarks

Management credited the quarter’s performance to strong clinical adoption, key product launches, and significant regulatory milestones that broadened Natera’s market opportunities.

• Oncology strength: The Signatera minimal residual disease (MRD) test achieved record clinical volumes, benefitting from FDA approval as a companion diagnostic and recognition by key U.S. and Japanese authorities. These milestones helped drive adoption among new accounts and increased usage across multiple tumor types.
• Enhanced prenatal screening: The launch of the improved Panorama non-invasive prenatal test (NIPT) addressed a longstanding gap in prenatal screening by improving performance in low fetal fraction cases, lowering the no-call rate, and winning over new physician accounts. Management cited strong early demand and positive feedback from obstetricians.
• Organ health reimbursement: Natera secured expanded Medicare coverage for organ transplant surveillance, increasing the number of covered tests for kidney, heart, and lung transplants. This policy change is expected to boost both test volume and average selling price (ASP) in the organ health segment.
• Commercial team investments: Prior investments in sales and medical affairs teams reached full productivity, contributing to broad-based volume growth and improved execution in both new and existing markets. Management highlighted the importance of these investments in sustaining above-market growth rates.
• Operating leverage and gross margins: Sequential improvement in gross margin was achieved through higher ASPs and operational efficiencies, even as costs of goods sold (COGS) temporarily rose from scaling new products. Management remains focused on further cost optimization as product volumes increase.

Drivers of Future Performance

Natera’s outlook is underpinned by volume-driven revenue growth, ongoing clinical adoption, and continued margin expansion as new products scale and reimbursement improves.

• Pipeline of clinical studies: Management expects multiple prospective study readouts in 2027 and beyond to support additional guideline inclusions and payer coverage, particularly for Signatera across new tumor types. These studies are designed to change clinical practice and unlock new reimbursement avenues.
• International expansion: The commercial launch of Signatera in Japan is expected to match or exceed U.S. adoption rates, supported by local guideline endorsements and strong distribution partnerships. Timely reimbursement decisions will be critical to accelerating market penetration.
• Cost efficiency projects: Ongoing investments in automation, artificial intelligence, and workflow optimization are expected to lower COGS for new products over the next 12 to 18 months, driving incremental gross margin improvements and supporting the path to profitability.

Catalysts in Upcoming Quarters

In upcoming quarters, StockStory analysts will closely monitor (1) further progress in securing expanded payer coverage and guideline inclusions for Signatera, (2) the commercial rollout and reimbursement ramp in Japan, and (3) the pace of prospective clinical study readouts supporting expanded product indications. Additionally, we will track improvements in cost of goods sold and operational efficiency as new products scale.

Natera currently trades at $322.17, up from $265.38 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).

High Quality Stocks for All Market Conditions

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.